Followers | 506 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Wednesday, October 29, 2014 9:33:26 AM
bullish very long term
$ISIS recent news/filings
## source: finance.yahoo.com
Wed, 29 Oct 2014 00:10:00 GMT ~ Regulus Announces Pricing of Public Offering of Common Stock
[PR Newswire] - Regulus will not receive any proceeds from the sale of the shares of common stock by Isis. Regulus anticipates using the net proceeds from the offering to fund preclinical and clinical development of its clinical candidates, RG-101 and RG-012, and its other initial microRNA development candidates, for the identification and validation of additional microRNA targets, and for capital expenditures, working capital and general corporate purposes. Deutsche Bank Securities and BMO Capital Markets are acting as joint book-running managers for the offering. Needham & Company, Wedbush PacGrow Life Sciences and FBR are acting as co-managers.
read full: http://finance.yahoo.com/news/regulus-announces-pricing-public-offering-001000158.html
*********************************************************
Tue, 28 Oct 2014 23:24:10 GMT ~ Lightning Round: GNC, Goldman and more
read full: http://www.cnbc.com/id/102128707?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=102128707
*********************************************************
Tue, 28 Oct 2014 23:00:00 GMT ~ Cramer: Time for this CEO to hit the road
read full: http://finance.yahoo.com/video/cramer-time-ceo-hit-road-230000748.html
*********************************************************
Fri, 17 Oct 2014 01:35:45 GMT ~ World Leading Clinical Expert to Present to Shareholders
[at noodls] - _ December 2008 9 October 2014 World Leading Clinical Expert Professor Peter Trainer to Present to Shareholders on Successful ATL1103 Phase II Trial Results Antisense Therapeutics Ltd (ASX:ANP or "the ...
read full: http://www.noodls.com/view/CD2300492046816E50F45395796490A01F74AD75
*********************************************************
Mon, 13 Oct 2014 20:50:28 GMT ~ Isis Pharmaceuticals Unveils Mid-Stage Data on ISIS-SMNRx
read full: http://finance.yahoo.com/news/isis-pharmaceuticals-unveils-mid-stage-205028724.html
*********************************************************
$ISIS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ISIS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ISIS/company-info
Ticker: $ISIS
OTC Market Place: Not Available
CIK code: 0000874015
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
Incorporated In: DE, USA
$ISIS share structure
## source: otcmarkets.com
Market Value: $5,466,452,765 a/o Oct 28, 2014
Shares Outstanding: 117,735,360 a/o Aug 01, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$ISIS extra dd links
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ISIS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ISIS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ISIS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/news - http://finance.yahoo.com/q/h?s=ISIS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ISIS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ISIS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ISIS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Isis+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Isis+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Isis+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.isip.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.isip.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.isip.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ISIS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874015&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ISIS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ISIS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ISIS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ISIS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ISIS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ISIS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ISIS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ISIS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ISIS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ISIS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ISIS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ISIS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ISIS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ISIS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ISIS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ISIS
$ISIS DD Notes ~ http://www.ddnotesmaker.com/ISIS
Recent IONS News
- Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed • PR Newswire (US) • 06/25/2024 10:55:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 01:29:02 PM
- Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema • PR Newswire (US) • 06/18/2024 11:00:00 AM
- Ionis to present at TD Cowen Genetic Medicines & RNA Summit • PR Newswire (US) • 06/17/2024 08:09:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 02:59:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:33:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 11:15:31 AM
- Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema • PR Newswire (US) • 05/31/2024 11:00:00 AM
- Ionis to hold donidalorsen Phase 3 data webcast • PR Newswire (US) • 05/28/2024 11:00:00 AM
- New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) • PR Newswire (US) • 05/23/2024 11:00:00 AM
- Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • GlobeNewswire Inc. • 05/16/2024 11:30:14 AM
- Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis • PR Newswire (US) • 05/16/2024 11:30:00 AM
- Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome • PR Newswire (US) • 05/16/2024 11:00:00 AM
- Ionis to host 2024 virtual Annual Meeting of Stockholders • PR Newswire (US) • 05/15/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 09:25:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:55:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 07:55:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 03:15:41 PM
- Ionis reports first quarter 2024 financial results • PR Newswire (US) • 05/07/2024 11:00:00 AM
- Ionis Publishes 2023 Corporate Responsibility Report • PR Newswire (US) • 04/25/2024 11:00:00 AM
- Ionis to hold first quarter 2024 financial results webcast • PR Newswire (US) • 04/23/2024 11:05:00 AM
- Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome • PR Newswire (US) • 04/07/2024 01:48:00 PM
- Ionis to present at upcoming investor conferences • PR Newswire (US) • 04/01/2024 11:05:00 AM
- Ionis to hold olezarsen Phase 3 data webcast • PR Newswire (US) • 03/28/2024 11:05:00 AM
- Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting • PR Newswire (US) • 03/25/2024 12:18:00 PM
FEATURED POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM